Key facts
- It has raised $1.6M across 2 recorded rounds; the latest was Seed Round ($970K) in Jul 2024.
- Notable investors include Creative Destruction Lab, United States Department of War, University of Toronto, Lorentzen Investments, Research Park at FAU.
- Triangulate Labs has filed 2 Form Ds with the SEC since 2023, most recently Jan 2025 ($970K sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Triangulate Labs
Funding rounds
2 roundsAbout Triangulate Labs
Developer of a 3-dimensional mapping technology designed to help dermatologists cure skin cancer. The company's technology uses a smartphone to capture a patient's skin without the need for standardized poses, which provides a high-quality, full-body digital map of the skin by incorporating the behavior of the human body's articulation and deformation into localization and coverage awareness, enabling patients to track and detect changes in the skin and identify any anomalies that need additional medical attention.
- Sector
- Healthcare
- HQ
- Boca Raton, FL, United States
- Founded
- 2017
- Employees
- 10
- Website
- triangulatelabs.com/
- Ownership
- Privately Held (backing)
Triangulate Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Triangulate Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Triangulate Labs in its N-PORT filings yet. We sweep new filings monthly.